| Aug 30 |
'This Is A Very Speculative Situation,' Jim Cramer On ADMA Biologics
|
| Aug 28 |
Delcath Systems, Inc. Announces Positive Results from Independent Study on Liver-Directed Therapy for Uveal Melanoma Patients
|
| Aug 28 |
Delcath Systems to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 27 |
Delcath stock jumps 15% on Hepzato Kit study publication
|
| Aug 27 |
Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients
|
| Aug 26 |
Delcath Systems, Inc. Announces Promising Results from Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors
|
| Aug 20 |
Delcath Systems Announces Poster Presentation at the 2024 ESMO Congress
|
| Aug 19 |
Delcath Is On Schedule For A Monster 2025: A Platform Valuation Awaits
|
| Aug 12 |
Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
| Aug 7 |
Delcath Systems Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
